Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2017

12.10.2016

The use of direct oral anticoagulants in inherited thrombophilia

verfasst von: Jessica W. Skelley, C. Whitney White, Angela R. Thomason

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

To review the use of the direct oral anticoagulant (DOAC) agents in inherited thrombophilia based on the literature. MEDLINE, International Pharmaceutical Abstracts, and Google Scholar searches (1970–May 2016) were conducted for case reports, case series, retrospective cohorts, or clinical trials using the key words: protein C deficiency, protein S deficiency, antithrombin deficiency, activated protein C resistance, Factor V Leiden, hypercoagulable, NOACs, dabigatran, apixaban, rivaroxaban, betrixaban, edoxaban, Xa inhibitor, direct thrombin inhibitor. Results were limited to English-only articles. Clinical studies evaluating the use of DOACs for hypercoagulable states related to inherited thrombophilia were selected and evaluated. Thrombophilia, a predisposition to thrombosis, manifests predominantly as venous thromboembolism. Causes of inherited thrombophilia include antithrombin deficiency, deficiencies of proteins C and S, and Factor V Leiden mutation. Many patients with thrombophilia receive anticoagulant therapy for primary or secondary prevention of VTE, historically either warfarin or a heparin product. DOAC’s have been considered as potential alternatives to traditional agents based on their pharmacologic activity. Case reports and a post-hoc analysis of a clinical trial have indicated positive results in patients with inherited thrombophilia and VTE. Positive results have been reported for the use of DOACs in inherited thrombophilia. Further robust studies are needed for definitive decision making by clinicians.
Literatur
1.
Rosendaal FR (1999) Venous thrombosis: a multicausal disease. The Lancet 353(9159):1167–1173CrossRef
2.
Couturaud F, Leroyer C, Julian JA et al (2009) Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. Chest J 136(6):1537–1545CrossRef
3.
Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW (1994) Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87(1):106–112CrossRefPubMed
4.
Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503–1506CrossRefPubMed
5.
Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277:1305–1307CrossRefPubMed
6.
Stefano VD, Finazzi G, Mannucci PM (1996) Inherited thrombophilia: pathogenesis, clinical syndrome, and management. Blood 87(9):3531–3544PubMed
7.
Dykes AC, Walker ID, Mcmahon AD, Islam SI, Tait RC (2001) A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 113(3):636–641CrossRefPubMed
8.
9.
10.
Heit JA (2007) Thrombophilia: common questions on laboratory assessment and management. Hematol Am Soc Hematol Educ Progr 2007:127–35
11.
Kearon C et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest J 149(2):315–352CrossRef
12.
Kearon C et al (2012) Antithrombotic therapy for VTE Disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest J 141(2 suppl):e419S–e494SCrossRef
13.
Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefPubMed
14.
Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRefPubMed
15.
Buller HR, Decousus H, Hokusai- VTE Investigators et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415CrossRefPubMed
16.
Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764–772CrossRefPubMed
17.
Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808CrossRefPubMed
18.
Buller HR, Prins MH, EINSTEIN- EP Investigators et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297CrossRefPubMed
19.
van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975CrossRefPubMed
20.
Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET (2013) New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 145(1):105–112CrossRefPubMed
21.
Gomez-Outes A, Terleira-Fernandez AI, Lecumberri R, Suarez-Gea ML, Vargas-Castrillon E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134(4):774–782CrossRefPubMed
22.
Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A (2012) Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 345:e7498CrossRefPubMedPubMedCentral
23.
van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12(3):320–328CrossRefPubMed
24.
Mantha S, Ansell J (2015) Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis 39(2):155–165CrossRefPubMed
25.
Chai-Adisaksopha C, Crowther M, IsayamaT (2014) Lim W The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124(15):2450–2458CrossRefPubMed
26.
Wu C, Alotaibi GS, Alsaleh K, Linkins LA (2015) Sean McMurtry M Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. Thromb Res 135(2):243–248CrossRefPubMed
27.
Castellucci LA, Cameron C, Le Gal G et al (2014) Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 312(11):1122–1135CrossRefPubMed
28.
Arachchillage DJ, Cohen H (2013) Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 15:331–340CrossRefPubMed
29.
30.
Win K, Rodgers GM (2014) New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 89:1017CrossRefPubMed
31.
Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112:947–950CrossRefPubMed
32.
Son M, Wypasek E, Celinska-Lowenhoff M, Undas A (2015) The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 135:1035–1036CrossRefPubMed
33.
Mavrakanas T, Bounameaux H (2011) The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 130(1):46–58CrossRefPubMed
34.
Chan NC, Bhagirath V, Eikelboom JW (2015) Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 11:343–351PubMedPubMedCentral
35.
Hermans C, Eeckhoudt S (2012) Lambert, C Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost 107:1189–1191CrossRefPubMed
36.
Wypasek E, Potaczek, DP, Alhenc-Gelas M, Undas A (2014) PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. Thromb Res 134:199–201CrossRefPubMed
37.
Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni EM (1998) Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92(7):2353–2358PubMed
38.
Cook RM, Rondina MT, Horton DJ (2014) Rivaroxaban for the long-term treatment of spontaneous ovarian vein thrombosis caused by factor V leiden homozygosity. Ann Pharm 48(8):1055–1060
39.
Plander M, Szendrei T, Bodó I, Iványi JL (2015) Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment. Ann Hematol 94:1257–1258CrossRefPubMed
40.
Schulman S, Kearon C, Kakkar AK et al (2013) RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709–718CrossRefPubMed
41.
Schulman S, Eriksson H, Goldhaber SZ et al (2014) Influence of Thrombophilia on the efficacy of dabigatran versus warfarin for extended treatment of acute venous thromboembolism in RE-MEDY. Blood 124(21):1544
42.
Hohnloser SH, Oldgren J, Yang S et al (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125:669–676CrossRefPubMed
43.
44.
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med 363:2499–2510CrossRef
45.
EINSTEIN- PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRef
46.
Ruis-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. The Lancet 376:1498–1509CrossRef
47.
Fawole A, Daw HA, Crowther MA (2013) Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 80(7):443–451CrossRefPubMed
48.
49.
50.
51.
52.
Martinuzzo ME, Barrera LH, D’adamo MA, Otaso JC, Gimenez MI, Oyhamburu J (2013) Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. doi:10.​1111/​ijlh.​12138 PubMed
53.
54.
Nakashima MO, Rogers HJ (2014) Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res 49(2):85–94CrossRefPubMedPubMedCentral
55.
Rivaroxaban [package insert] (2011) Janssen Pharmaceuticals, Inc., Titusville
56.
Apixaban [package insert] (2012) Bristol-Myers Squibb Company, Princeton
57.
Edoxaban [package insert] (2015) Daiichi Sankyo, Inc., Parsippany
58.
Dabigatran [package insert] (2015) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield
59.
January CT, Wann LS, Alpert JS et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–e76CrossRefPubMed
Metadaten
Titel
The use of direct oral anticoagulants in inherited thrombophilia
verfasst von
Jessica W. Skelley
C. Whitney White
Angela R. Thomason
Publikationsdatum
12.10.2016
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1428-2

Weitere Artikel der Ausgabe 1/2017

Journal of Thrombosis and Thrombolysis 1/2017 Zur Ausgabe

ReviewPaper

Plasminogen deficiency

OriginalPaper

Endocan: a novel biomarker associated with well-developed coronary collateral circulation in patients with stable angina and chronic total occlusion

OriginalPaper

Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study

OriginalPaper

Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke

Letter to the Editor

Assessing in vivo platelet activation in patients with liver diseases

OriginalPaper

Direct oral anticoagulants in hypercoagulable states

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise